Cheapest Wegovy alternative in 2026: the verified routes by cost

The short answer. The cheapest way to get the same clinical result as Wegovy injectable depends on whether "alternative" means a different semaglutide product, a different drug, or a different payment route. Compounded semaglutide runs $129 to $178 a month and is the same active molecule. The new Wegovy oral pill runs $149 a month through NovoCare Pharmacy at a promotional price. Zepbound (tirzepatide) via LillyDirect runs $349 to $499 a month and has slightly better average efficacy in trials. Insurance prior authorization is the cheapest path of all for patients whose plan covers GLP-1s, often $0 to $50 a month. The right answer depends on whether you are optimizing for lowest cost, lowest regulatory risk, or lowest wait time.

Option 1: compounded semaglutide

Compounded semaglutide is the cheapest path for most cash-pay patients. It is the same active molecule as Wegovy (semaglutide), mixed by a 503A compounding pharmacy rather than manufactured by Novo Nordisk under its new-drug application. The cash price runs $129 to $178 a month for the injectable, compared to $349 to $499 for the branded NovoCare injectable.

Among the programs we track, Noom Med is the lowest verified all-in at $129 a month, billed quarterly, month-to-month cancel. Mochi Health is the cheapest flat-priced option at $178 a month at every dose tier, including the 1.7 mg and 2.4 mg maintenance doses where most programs charge more. Strut Health and Klarity Health sit in the $149 to $199 range with no membership fee.

The trade-off is regulatory. The FDA declared the semaglutide shortage resolved in October 2024, which narrowed the legal basis for routine 503A compounding. Programs that still prescribe compounded semaglutide operate under a personalization claim or medical-necessity exception. The supply can be disrupted faster than the supply of branded NovoCare product. Read our full compounded semaglutide comparison before choosing on price alone.

Option 2: Wegovy oral pill

Novo Nordisk launched an oral semaglutide tablet for weight loss in 2026. The pill is FDA-approved and uses the same mechanism as the injectable, but in pill form rather than a weekly injection. Through NovoCare Pharmacy, the self-pay price for the oral tablet is $149 a month for the 1.5 mg and 4 mg doses (promotional pricing through August 31, 2026) and $199 a month for the 0.25 mg and 0.5 mg starting doses.

At $149 a month, the oral Wegovy is cheaper than the injectable NovoCare Wegovy by $200 or more. It is also a branded, FDA-approved product with the full NovoCare supply chain, which eliminates the regulatory exposure that compounded programs carry.

The limit: the oral pill is still a newer product with less long-term efficacy data than the injectable. The injectable Wegovy achieved 15 to 17 percent average body-weight reduction in the STEP trials; the oral semaglutide OASIS trials showed 15 percent at the highest dose, close but with a narrower margin. The pill also requires strict fasting protocols at dosing time that the injectable does not. For patients who want the lowest-friction branded path, the oral pill at $149 is the most affordable FDA-approved Wegovy available right now.

Option 3: Zepbound (tirzepatide) via LillyDirect

Zepbound is not semaglutide. It is tirzepatide, a dual GIP and GLP-1 receptor agonist manufactured by Eli Lilly. The SURMOUNT trials showed 20 to 22 percent average weight loss at the highest doses, versus 15 to 17 percent for semaglutide (Wegovy) at comparable doses. The mechanism is different and the average efficacy edge is real, though individual response varies.

Through LillyDirect, Zepbound runs $349 to $499 a month at the self-pay cash price, roughly the same as NovoCare Wegovy injectable. It is not cheaper than Wegovy on a dollar basis, but it is an alternative when Wegovy supply is disrupted or when a patient has not responded adequately to semaglutide. Telehealth programs that prescribe Zepbound include Ro Body and PlushCare; both run the LillyDirect prescription path for self-pay patients.

Option 4: insurance prior authorization

For patients whose commercial insurance covers Wegovy or Zepbound for obesity, prior authorization is the cheapest route available. The drug itself costs $0 to $50 a month as a copay once PA is approved. The labor is the prior auth paperwork: BMI documentation, comorbidity attestation, evidence of prior weight-loss attempts, clinician sign-off. Programs like PlushCare ($19.99/mo) and Noom Med ($69/mo) handle the PA process as part of the membership.

PA approval rates vary. Roughly 40 to 60 percent of first-pass GLP-1 prior auth requests are denied. The appeal success rate is meaningfully higher, often 60 to 75 percent. If your plan covers GLP-1s for obesity, filing the PA and appealing a denial is the work that gets the monthly cost from $400+ to $25. Our PA letter template library has 200 ready-to-edit templates across 20 plans and 10 qualifying conditions.

Which route fits which situation

The price-risk trade-off

Every cheaper alternative to Wegovy injectable carries a cost that does not appear on the monthly bill. Compounded semaglutide carries regulatory exposure: the program's pharmacy can be shut down mid-treatment. The oral pill's efficacy data is thinner than the injectable's. The prior auth route requires paperwork and a possible appeal. None of these costs are reasons to avoid the alternatives, but they are reasons to know them before signing up.

The clearest risk-adjusted choice for most cash-pay patients who want an FDA-approved product: the Wegovy oral pill at $149 a month through NovoCare while the promotional pricing holds. For patients willing to accept compounded regulatory risk, Noom Med at $129 a month is cheaper with the same molecule. For patients with insurance, the prior auth path is cheapest by a large margin once approved.

Frequently asked questions

What is the cheapest alternative to Wegovy in 2026?

For cash-pay patients, compounded semaglutide through Noom Med at $129 a month is the cheapest verified option. It is the same active molecule as Wegovy, dispensed by a 503A compounding pharmacy. The Wegovy oral pill through NovoCare is the cheapest branded FDA-approved alternative at $149 a month for the 1.5 mg and 4 mg doses (promotional pricing through August 31, 2026). For insured patients, prior authorization for Wegovy or Zepbound gets the monthly cost to $0 to $50 as a copay.

Is compounded semaglutide the same as Wegovy?

The active molecule is the same: semaglutide. The manufacturing is different. Wegovy is manufactured by Novo Nordisk under FDA new-drug approval, with standardized potency, sterility, and formulation testing. Compounded semaglutide is mixed by a 503A pharmacy under a patient-specific prescription. The clinical effect is comparable in patient-reported outcomes, but the formal evidence base is thinner and the supply is less stable. See our compounded versus FDA-approved comparison for what is actually different.

Is the Wegovy pill as effective as the injectable?

Close, but slightly lower in the trial data. The OASIS trials for oral semaglutide showed 15 percent average body-weight reduction at the highest dose. The STEP trials for injectable Wegovy showed 15 to 17 percent. The difference is within the range of individual variation. The pill also requires strict fasting protocols (no food or liquid for 30 minutes after dosing) that the injectable does not. For most patients, the difference in average efficacy is small; the difference in administration preference is personal.

Why is Zepbound more expensive than compounded semaglutide but considered a Wegovy alternative?

Zepbound (tirzepatide) is an alternative because it treats the same condition (obesity) through a related but different mechanism (dual GIP and GLP-1 agonism versus semaglutide's single GLP-1 agonism). The SURMOUNT trials showed 20 to 22 percent average weight loss versus 15 to 17 percent for Wegovy, which makes it a meaningful clinical step up for patients who tolerate tirzepatide. The cash price ($349 to $499/mo via LillyDirect) is similar to Wegovy injectable; it is not cheaper. It is an alternative when Wegovy fails or is unavailable, not when price is the constraint.

How do I get Wegovy or Zepbound covered by insurance?

File a prior authorization request through your telehealth provider. Programs like PlushCare and Noom Med handle the PA paperwork as part of the membership fee. You need BMI documentation, a qualifying indication (obesity BMI 30+, or BMI 27+ with a comorbidity), and evidence of prior weight-loss attempts in some plans. If denied, appeal. The appeal success rate is 60 to 75 percent. Our PA letter template library has 200 plan-specific templates for the most common denial reasons.

Related

• Wegovy cost without insurance 2026: the real cash-pay paths
• Cheapest compounded semaglutide in 2026: the verified low-cost list
• Compounded vs FDA-approved semaglutide: what is actually different
• 200 GLP-1 prior authorization letter templates
• Cheapest GLP-1 weight loss programs 2026: verified programs under $200